| Literature DB >> 26997844 |
Julia Yan Yu Chan1, Bonnie Nk Choy1, Alex Lk Ng1, Jennifer Wh Shum1.
Abstract
Despite being documented in medical history from over 2400 years ago, primary congenital glaucoma (PCG), being a disease with low incidence rate, remains a challenge to ophthalmologists. The article provides a broad overview on the pathophysiology and diagnostic approach to PCG with major emphasis on the treatment options of PCG. While reviewing on the well-established treatment options, namely goniotomy, trabeculo-tomy and combined trabeculotomy-trabeculectomy, emphasis has also been made to recent updates on secondary treatments: trabeculectomy, antimetabolites, glaucoma-drainage devices and cyclodestructive procedures. It is, however, important to note that the rarity of PCG places limitations on study design, most studies are, thus, retrospective, nonrandomized and have different definitions of surgical success. Ophthalmologists need to interpret the results with critical thinking and formulate individual treatment plans for each patient. How to cite this article: Yu Chan JY, Choy BNK, Alex LK Ng, Shum JWH. Review on the Management of Primary Congenital Glaucoma. J Curr Glaucoma Pract 2015;9(3):92-99.Entities:
Keywords: Childhood glaucoma; Goniotomy; Pediatric glaucoma surgery.; Primary congenital glaucoma; Trabeculotomy
Year: 2016 PMID: 26997844 PMCID: PMC4779948 DOI: 10.5005/jp-journals-10008-1192
Source DB: PubMed Journal: J Curr Glaucoma Pract ISSN: 0974-0333
Table 1: Hoskins classification
Table 2: Medications/agents that influence the IOP
| Induction agents | Nitrous oxide | ― | |||
| Cyclopropane | |||||
| Halothane[ | |||||
| Muscle relaxants | Tubocurarine[ | Succinylcholine[ | |||
| Gallamine | |||||
| General | Barbiturate | Ketamine[ | |||
| anesthetics | Morphine | ||||
| Sevoflurane[ |
Table 3: Effect and side effects of antiglaucoma medications in PCG patients
| Beta blockers | Fair, no effect in 39-54% of patients | Possibility of apnea | To exclude asthma/cardiac anomaly before use. Check availability of 0.25% timolol, which is preferable in children | ||||
| Carbonic anhydrase inhibitors | Fair | Growth suppression, metabolic acidosis | ― | ||||
| Prostaglandin analogs | Poor, no effect in 50-80% of patients | Mainly local side effects as observed in adults | Predictors of poor response include severity glaucoma and young age of presentation | ||||
| Alpha-2 agonists | ― | CNS suppression | Contraindicated in children | ||||
| Parasympathomimetics | Poor | ― | Limited use in pediatric patient |